Continue to Innovate Services, Therapies and Products

• Expand portfolio

  • First recombinant FVIII manufactured without the addition of human or animal proteins

• Expand customer base / recombinant penetration

• Differentiate products and introduce new services

  • Advoy
  • Delivery devices
  • Leverage service capabilities

• Add capacity in Thousand Oaks & Neuchatel

rFVIII in the Future

Previous slide

Next slide

Back to first slide

View graphic version